125 related articles for article (PubMed ID: 38360140)
1. STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2
Cheng C; Liang S; Yue K; Wu N; Li Z; Dong T; Dong X; Ling M; Jiang Q; Liu J; Huang XJ
Cancer Lett; 2024 Apr; 587():216730. PubMed ID: 38360140
[TBL] [Abstract][Full Text] [Related]
2. Identification of the immunosuppressive effect of γδ T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia.
Liang S; Dong T; Yue K; Gao H; Wu N; Liu R; Chang Y; Hao L; Hu L; Zhao T; Jiang Q; Huang XJ; Liu J
Front Immunol; 2022; 13():1009709. PubMed ID: 36325350
[TBL] [Abstract][Full Text] [Related]
3. High
Kong X; Zheng J; Liu X; Wang W; Jiang X; Chen J; Lai J; Jin Z; Wu X
Front Immunol; 2022; 13():823352. PubMed ID: 35222403
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
5. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
6. CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2
Dong T; Wu N; Gao H; Liang S; Dong X; Zhao T; Jiang Q; Liu J
Ann Hematol; 2022 Oct; 101(10):2195-2208. PubMed ID: 35920929
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2
Bruni E; Cazzetta V; Donadon M; Cimino M; Torzilli G; Spata G; Leonardi G; Dieli F; Mikulak J; Mavilio D
J Immunother Cancer; 2019 Dec; 7(1):347. PubMed ID: 31829255
[TBL] [Abstract][Full Text] [Related]
8. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
[No Abstract] [Full Text] [Related]
9. Higher TIGIT+ γδ T
Hou Q; Wang P; Kong X; Chen J; Yao C; Luo X; Li Y; Jin Z; Wu X
Front Immunol; 2024; 15():1321126. PubMed ID: 38711501
[TBL] [Abstract][Full Text] [Related]
10. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Knight A; Piskacek M; Jurajda M; Prochazkova J; Racil Z; Zackova D; Mayer J
Cancer Immunol Immunother; 2023 May; 72(5):1209-1224. PubMed ID: 36376516
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
12. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
13. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.
Hunter S; Willcox CR; Davey MS; Kasatskaya SA; Jeffery HC; Chudakov DM; Oo YH; Willcox BE
J Hepatol; 2018 Sep; 69(3):654-665. PubMed ID: 29758330
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.
Sacchi A; Tumino N; Sabatini A; Cimini E; Casetti R; Bordoni V; Grassi G; Agrati C
Front Immunol; 2018; 9():1271. PubMed ID: 29928279
[TBL] [Abstract][Full Text] [Related]
15. Suppressive activity of Vδ2
Schilbach K; Krickeberg N; Kaißer C; Mingram S; Kind J; Siegers GM; Hashimoto H
Cancer Immunol Immunother; 2020 Apr; 69(4):593-610. PubMed ID: 31982940
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional heterogeneity of peripheral γδ T cells in pulmonary TB and HIV patients in Addis Ababa, Ethiopia.
Negash M; Tsegaye A; Wassie L; Howe R
BMC Infect Dis; 2018 Sep; 18(1):464. PubMed ID: 30219039
[TBL] [Abstract][Full Text] [Related]
17. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies.
Rao A; Agrawal A; Borthakur G; Battula VL; Maiti A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417915
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus drives Vδ2neg γδ T cell inflation in many healthy virus carriers with increasing age.
Alejenef A; Pachnio A; Halawi M; Christmas SE; Moss PA; Khan N
Clin Exp Immunol; 2014 Jun; 176(3):418-28. PubMed ID: 24547915
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals.
Ryan PL; Sumaria N; Holland CJ; Bradford CM; Izotova N; Grandjean CL; Jawad AS; Bergmeier LA; Pennington DJ
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14378-14383. PubMed ID: 27911793
[TBL] [Abstract][Full Text] [Related]
20. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells.
Siegers GM; Dhamko H; Wang XH; Mathieson AM; Kosaka Y; Felizardo TC; Medin JA; Tohda S; Schueler J; Fisch P; Keating A
Cytotherapy; 2011 Jul; 13(6):753-64. PubMed ID: 21314241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
